[Federal Register Volume 68, Number 25 (Thursday, February 6, 2003)]
[Notices]
[Pages 6183-6184]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-2913]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Sec.  1301.34 of title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on November 4, 
2002, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made 
application by renewal to the Drug Enforcement Administration to be 
registered as an importer of the basic classes of controlled substances 
listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methaqualone (2565)........................  I
Lysergic acid diethylamide (7315)..........  I
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
Acetyldihydrocodeine (9051)................  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Tilidine (9750)............................  I
Amphetamine (1100).........................  II

[[Page 6184]]

 
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Hydrocodone (9193).........................  II
Levorphanol (9220).........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The firm plans to import small reference standard quantities of 
finished commercial product from its sister company in Switzerland for 
sale to its customers for drug testing and pharmaceutical research and 
development.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of these basic classes of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention DEA 
Federal Register Representative (CCR), and must be filed no later than 
March 10, 2003.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e),and (f). As noted in a previous notice at 40 FR 43745-46 (September 
23, 1975), all applicants for registration to import the basic classes 
of any controlled substances in Schedule I or II are and will continue 
to be required to demonstrate to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration that the 
requirements for such registration pursuant to 21 U.S.C. 958(a), 21 
U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), (d), (e), and (f) are 
satisfied.

    Dated: January 27, 2003.
Laura M.Nagel,
deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-2913 Filed 2-5-03; 8:45 am]
BILLING CODE 4410-09-M